NORTHBROOK, Ill. -- (BUSINESS WIRE) -- Marathon Pharmaceuticals, LLC today announced Dave Bradshaw has joined the company as executive director of manufacturing. In this role, Bradshaw will oversee the manufacturing and supply operations for Marathon Pharmaceuticals' rapidly growing portfolio of treatments.
Bradshaw, 52, has over 30 years of experience in pharmaceutical manufacturing. He previously served as senior director of manufacturing for Recordati Rare Diseases, Lundbeck, Inc. and Ovation Pharmaceuticals. Bradshaw also held leadership roles at Biomira, Chiron and Pathogenesis.
As part of Marathon’s executive team, Bradshaw is responsible for ensuring that the drug supply chain, from raw material acquisition to final product delivery, meets Marathon’s high standards for timeliness, quality and regulatory compliance.
“Excellence in manufacturing is a critical part of Marathon’s commitment to making medications available for the patients who need them,” Said Dr. Michael Rice, Marathon Pharmaceuticals vice president of technical operations. “Dave’s deep experience in complex pharmaceutical manufacturing will be an important asset as Marathon continues to commercialize new treatments.”
Bradshaw holds a degree in chemistry from Fairleigh Dickinson University. He will be based out of New Jersey.
Marathon Pharmaceuticals, LLC is a biopharmaceutical company that develops new treatments for rare diseases and makes small volume, hard-to-manufacture medications available to people who need them. Marathon is focused on providing medicine to patients who currently have no treatment options. The company manufactures prescription medications and is developing a pipeline of treatments for rare cancers and neurological disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago and New Jersey. For more information visit www.marathonpharma.com.